Skip to content

SANGUI BIOTECH INTERNATIONAL INC: 10-Q filed 2016-02-22

What SANGUI BIOTECH INTERNATIONAL INC reported in its quarterly report filed 2016-02-22 (fiscal Q2 2016): 22 published measures, 64 facts as tagged in accession 0001551163-16-000304.

This filing

Form
10-Q (quarterly report)
Filed
2016-02-22
Fiscal period
fiscal Q2 2016
Accession
0001551163-16-000304 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SANGUI BIOTECH INTERNATIONAL INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-12-31185,701USD
At 2015-06-30122,099USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-12-31-333,214USD
At 2015-06-30-339,834USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-12-3188,073USD
At 2015-06-3017,672USD
At 2014-12-3193,006USD
At 2014-06-3098,148USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-07-01 to 2015-12-31-453,057USD184
2014-07-01 to 2014-12-31-383,558USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2015-07-01 to 2015-12-31-178,143USD184
2014-07-01 to 2014-12-31-318,740USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-10-01 to 2015-12-3115,385USD92
2015-07-01 to 2015-12-3126,856USD184
2014-10-01 to 2014-12-3131,166USD92
2014-07-01 to 2014-12-31104,906USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2015-07-01 to 2015-12-31232,775USD184
2014-07-01 to 2014-12-31280,942USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2015-07-01 to 2015-12-316,977USD184
2014-07-01 to 2014-12-3132,196USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-12-31-36,614,356USD
At 2015-06-30-36,160,646USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-88,164USD92
2015-07-01 to 2015-12-31-249,590USD184
2014-10-01 to 2014-12-31-173,702USD92
2014-07-01 to 2014-12-31-381,747USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-12-31185,701USD
At 2015-06-3072,099USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-14,926USD92
2015-07-01 to 2015-12-31-16,327USD184
2014-10-01 to 2014-12-31-902USD92
2014-07-01 to 2014-12-31-1,811USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-12-31518,915USD
At 2015-06-30461,933USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-10-01 to 2015-12-31103,405USD92
2015-07-01 to 2015-12-31276,217USD184
2014-10-01 to 2014-12-31204,710USD92
2014-07-01 to 2014-12-31486,255USD184

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2015-10-01 to 2015-12-3115,241USD92
2015-07-01 to 2015-12-3126,627USD184
2014-10-01 to 2014-12-3131,008USD92
2014-07-01 to 2014-12-31104,508USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-10-01 to 2015-12-311,455USD92
2015-07-01 to 2015-12-3135,507USD184
2014-10-01 to 2014-12-3141,874USD92
2014-07-01 to 2014-12-31134,977USD184

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-12-314,621,430USD
At 2015-06-304,621,430USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2015-12-31412,900USD
At 2015-06-30169,589USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-290,883USD92
2015-07-01 to 2015-12-31-453,710USD184
2014-10-01 to 2014-12-31-174,604USD92
2014-07-01 to 2014-12-31-383,558USD184

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-284,729USD92
2015-07-01 to 2015-12-31-435,057USD184
2014-10-01 to 2014-12-31-161,760USD92
2014-07-01 to 2014-12-31-355,928USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-10-01 to 2015-12-31101,950USD92
2015-07-01 to 2015-12-31240,710USD184
2014-10-01 to 2014-12-31162,836USD92
2014-07-01 to 2014-12-31351,278USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2015-07-01 to 2015-12-31-16,860USD184
2014-07-01 to 2014-12-31-37,055USD184

Inspect the source

Entity
SANGUI BIOTECH INTERNATIONAL INC / CIK 0001104280
Captured
SEC response SHA-256
80929a3d07bdd3be99cfb5858d464edb9844d0e622d958ee5dce9515baeeed6f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001104280.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))